Product Details of 41575-94-4. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.. Author is DeBoer, Rebecca J; Umutoni, Victoria; Bazzett-Matabele, Lisa; Katznelson, Ethan; Nguyen, Cam; Umwizerwa, Aline; Bigirimana, Jean Bosco; Paciorek, Alan; Nsabimana, Nicaise; Ruhangaza, Deogratias; Ntasumbumuyange, Diomede; Shulman, Lawrence N; Triedman, Scott A; Shyirambere, Cyprien.
OBJECTIVE: Most cervical cancer cases and deaths occur in low- and middle-income countries, yet clinical research from these contexts is significantly underrepresented. We aimed to describe the treatment quality, resource-driven adaptations, and outcomes of cervical cancer patients in Rwanda. METHODS: A retrospective cohort study was conducted of all patients with newly diagnosed cervical cancer enrolled between April 2016 and June 2018. Data were abstracted from medical records and analyzed using descriptive statistics, Kaplan Meier methods, and Cox proportional hazards regression. RESULTS: A total of 379 patients were included; median age 54 years, 21% HIV-infected. A majority (55%) had stage III or IV disease. Thirty-four early-stage patients underwent radical hysterectomy. Of 254 patients added to a waiting list for chemoradiation, 114 ultimately received chemoradiation. Of these, 30 (26%) received upfront chemoradiation after median 126 days from diagnosis, and 83 (73%) received carboplatin/paclitaxel while waiting, with a median 56 days from diagnosis to chemotherapy and 207 days to chemoradiation. There was no survival difference between the upfront chemoradiation and prior chemotherapy subgroups. Most chemotherapy recipients (77%) reported improvement in symptoms. Three-year event-free survival was 90% with radical hysterectomy (95% CI 72-97%), 66% with chemoradiation (95% CI 55-75%), and 12% with chemotherapy only (95% CI 6-20%). CONCLUSIONS: Multi-modality treatment of cervical cancer is effective in low resource settings through coordinated care and pragmatic approaches. Our data support a role for temporizing chemotherapy if delays to chemoradiation are anticipated. Sustainable access to gynecologic oncology surgery and expanded access to radiotherapy are urgently needed.
In addition to the literature in the link below, there is a lot of literature about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Product Details of 41575-94-4, illustrating the importance and wide applicability of this compound(41575-94-4).
Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics